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1. SUMMARY 
 
Background: Approximately 10% of hypertensives have resistant hypertension, even if 
adequate pharmacological therapy is established. In this regard renal nerve denervation 
(RDN) could represent a valid alternative treatment. Methods: In a retrospective analysis 
with a follow-up of 6, 12 and 24 months we investigated the efficacy and safety of 
catheter-based renal artery ablation in 57 patients undergoing RDN with multiple renal 
nerve ablation in both renal arteries.  In addition to medical antihypertensive therapy 
(4.2±1.4 drugs per patient), RDN using three different ablation systems was performed in 
patients with confirmed resistant hypertension (systolic blood pressure >140 mmHg in 
spite of three drugs including a diuretic). The primary endpoint was the change in office 
ambulatory systolic blood pressure from baseline to 6, 12 and 24 months follow-up after 
RDN. The primary safety endpoint was the change in plasma creatinine levels after 12 and 
24 months compared to baseline. Results: The mean office systolic blood pressure at 
baseline was 167.6±22.4and after 6, 12 and 24 months averaged 143.5±21.1 (p<0.05), 
141.1±21.1 (p<0.05) and 139.4±19.6 mmHg (p<0.05) respectively, with an average of 
15.1±5, three nerve ablations performed. No significant changes in plasma creatinine levels 
were observed at 12 (p=0.421) and at 24 months (p=0.217). There were no complications 
after RDN nor any relevant adverse vascular, renal or cardiovascular events were observed 
except in one patient in whom a covered stent had to be placed at the femoral puncture site.  
Conclusions: In this study in all comers with resistant hypertension RDN, if performed 
adequately in number of ablations and energy delivery, is an efficient and safe treatment 
option to lower office and 24h blood pressure. Whether these blood pressure lowering 
effects will lead to a reduction of the cardiovascular morbidity and mortality will require 
further studies. 
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2. LIST OF ABBREVIATIONS USED 
 
RDN= renal nerve denervation 
 
BP= blood pressure 
 
HBPM= home blood pressure measurement 
 
ABPM= ambulatory blood pressure measurement 
 
SBP= systolic blood pressure 
 
DBP= diastolic blood pressure 
 
ACE= angiotensin converting enzymee 
 
AT= angiotensin 
 
ACTH= adrenocorticotropic hormone 
 
MRI= magnetic resonance imaging 
 
RAAS= renin angiotensin aldosterone system 
 
ESC= European society of cardiology 
 
eGFR= estimated glomerular filtration rate 
 
BMI= body mass index 
 
CAD= coronary artery disease 
 
CKD= chronic kidney disease 
 
COPD= chronic obstructive pulmonary disease 
 
AF= atrial fibrillation 
 
OAC= oral anticoagulation 
 
CA= calcium antagonists 
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3. INTRODUCTION 
 
3.1 Relevance of the problem 
 
Arterial hypertension is highly prevalent in the overall population, in particular in adults 
and in the elderly, and represents one of the major cardiovascular risk factors for 
myocardial infarction and stroke [1, 2]. Both these events exhibit a linear relationship with 
blood pressure and particularly stroke is tightly linked to elevated blood pressure and age 
[3,4]. Moreover, high blood pressure carries an increased risk of developing vascular 
dementia [5]. In over 95% of patients, no apparent cause for the elevated blood pressure 
values can be found, a condition that has been defined as essential hypertension [6]. 
Despite lifestyle modification and the availability of effective antihypertensive drugs, 
blood pressure control remains suboptimal worldwide. Several factors account for that 
problem, among them non-compliance of physicians and patients, untreated secondary 
forms of hypertension and true treatment-resistant hypertension (i.e. blood pressure (BP) > 
140/90 mmHg in spite of 3 antihypertensive drugs including a diuretic). 
 
3.2 Hypertension 
3.2.1 Definition 
According to the latest American College of Cardiology Guidelines [7] BP should be 
categorized as normal, elevated, or stages 1 or 2 hypertension to prevent and treat high BP. 
Normal BP is defined as <120/<80 mm Hg; elevated BP 120-129/<80 mm Hg; 
hypertension stage 1 is 130-139 or 80-89 mm Hg, and hypertension stage 2 is ≥140 or ≥90 
mm Hg. Prior to labeling a person with hypertension, it is important to use an average 
based on ≥2 readings obtained on ≥2 occasions to estimate the individual’s level of BP. 
Out-of-office and self-monitoring of BP measurements are recommended to confirm the 
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diagnosis of hypertension and for titration of BP-lowering medication, in conjunction with 
clinical interventions and telehealth counseling. Corresponding BPs based on site/methods 
are: office/clinic 140/90, home blood pressure measurement (HBPM) 135/85, daytime 
ambulatory blood pressure measurement (ABPM) 135/85, nighttime ABPM 120/70, and 
24-hour ABPM 130/80 mm Hg. In adults with an untreated systolic BP (SBP) >130 but 
<160 mm Hg or diastolic BP (DBP) >80 but <100 mm Hg, it is reasonable to screen for the 
presence of white coat hypertension using either daytime ABPM or HBPM prior to 
diagnosis of hypertension. In adults with elevated office BP (120-129/<80) but not meeting 
the criteria for hypertension, screening for masked hypertension with daytime ABPM or 
HBPM is reasonable. According to the European Guidelines, Hypertension [8] is defined 
as a systolic blood pressure value at rest of> 140 mmHg and / or a diastolic blood pressure 
value at rest of> 90 mmHg (Table 1). 
 
Table 1. Definition and classification of blood pressure according to Mancia et al, 2013. 
Classification SBP (mmHg)   DBP (mmHg) 
Optimal <120 And <80 
Normal <140 and/or <90 
Hypertension Grade 1 (mild) 140-159 and/or 90-99 
Hypertonie Grade 2 (moderate) 160-179 and/or 100-109 
Hypertonie Grade 3 (severe) ≥180 and/or ≥110 
Isolated systolic Hypertension ≥140 And <90 
 
 
3.2.2. Epidemiology 
Arterial hypertension is highly prevalent in the overall population, but particularly in adults 
and the elderly (Figure 1) [1]. Systolic blood pressure especially increases with age due to 
a loss in elasticity of the vasculature and hence a loss of the “White Coat Effect”. In 
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Western countries, around 20% of the adult population have elevated blood pressure values 
(above 140/90 mmHg) making it one of the most important cardiovascular risk factors. 
 
Figure 1. Percent of population with high blood pressure according to age (from Rosamond et al., 
Circulation. 2008;117: e25-146.  
 
 
3.2.3 Etiology 
In patients considered for renal sympathetic denervation, secondary forms of hypertension 
must be excluded prior to the procedure [9].  In over 95% of the patients, no apparent 
cause for the elevated blood pressure values can be found, a condition, which is referred to 
as essential hypertension [6]. It is likely that this condition has a hereditary basis, as it is 
seen to run in families. In fact, the risk of developing high blood pressure with advancing 
age increases three to five–fold if one or two parents respectively are hypertensive [10]. 
Recently, it has been identified that genes themselves account for small changes in blood 
pressure [11]. Furthermore, the condition is more prevalent in certain populations over 
others (the so-called “low blood pressure populations”) [12, 13]. Besides a genetic 
disposition, dietary factors such as sodium and potassium intake as well as obesity have 
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been linked to essential hypertension. Of note, an over-activation of the sympathetic 
nervous system is often associated with essential hypertension. Renovascular hypertension 
is the most common curable form of secondary hypertension. Its prevalence ranges from 
between 1-3% in the hypertensive population but is more common in referral centers [14]. 
Two forms of renovascular hypertension can be distinguished: 1) Fibromuscular dysplasia 
and 2) atherosclerotic renal artery stenosis [15]. Both are amenable to percutaneous renal 
angioplasty [16, 17], and in the case of atherosclerotic lesions, to stenting as well [18]. 
Most forms of chronic kidney disease involve both kidneys, and lead to a steady decline in 
renal function over years and decades. Hypertension is associated with all forms of chronic 
kidney disease, in particular diabetic glomerulosclerosis (characterized by Kimmelstiel-
Wilson lesions on renal biopsy) and chronic glomerulonephritis [19]. Specific treatment 
modalities are rarely available, although inhibitors of the renin-angiotensin system (i.e., 
ACE-inhibitors and AT-receptor antagonists) reduce proteinuria and delay the decay in 
kidney function over time [9, 20]. In 1955 Jerome Conn described patients with 
hypertension, hypokalemia and adenomas of the adrenal cortex (the so-called “Conn’s 
syndrome”) [21]. Mineralocorticoid hypertension is characterized by elevated plasma 
aldosterone levels and suppressed plasma renin activity reflecting an autonomous 
aldosterone secretion by the adenoma [22]. Localization of the adenoma is best performed 
with computer tomography [12]. Patients with phaeochromocytoma typically experience 
palpitations, sweating and sometimes headaches due to sudden releases of catecholamines 
from the tumor. The diagnosis involves either computer tomography or magnetic 
resonance imaging [9, 23, 24]. Catecholamine levels in plasma or in urine (metanephrine, 
vanillinic acid) are typically elevated [23, 25]. Hypertension is one of the most 
distinguishing features of endogenous Cushing’s syndrome. The diagnosis is based on 
clinical observations and laboratory parameters (i.e., morning plasma cortisol, 24-hour 
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cortisol metabolites in urine) [6]. The latter often requires a cortisol-suppression test to 
distinguish Cushing’s syndrome from elevated cortisol values in simple obesity. True 
Cushing’s disease due to a pituitary adenoma producing ACTH should be distinguished 
from a cortisol-producing adrenal adenoma or bilateral adrenal hyperplasia, primarily by 
using imaging techniques such as MRI and/or adrenal scintigraphy. In the former clinical 
condition, removal of the tumor by trans-sphenoidal hypophysectomy is the treatment of 
choice, whereas adrenal tumors are managed by unilateral adrenalectomy. Determining 
possible secondary causes of hypertension is an important part in diagnosing patients with 
elevated blood pressure. All secondary causes of hypertension, including the less common 
(renal parenchymal disease, renovascular disease, phaeochromocytoma, primary 
aldosteronism (Conn’s syndrome), Cushing’s syndrome, coarctation of the aorta, thyroid 
dysfunction (hypo or hyperthyroidism), primary hyperparathyroidism, acromegaly, 
obstructive sleep apnea, drug/toxin-induced, monogenic renal tubular syndromes, pre-
eclampsia),  should always be excluded in severe hypertension, resistant hypertension or 
those aged <40 before starting or continuing long-term conventional pharmacological 
treatment. 
 
3.2.4 Diagnostic 
Although blood pressure itself was discovered by William Harvey as early as the 17th 
century, it could not be quantified until about 100 years later, when Stephen Hales used a 
cannula inserted into the carotid artery to determine blood pressure in a horse. After all, it 
was Scipione Riva-Rocci who, over a hundred years later, developed a first practical cuff 
for blood pressure measurement. Nicolai Korotkoff improved the method of Riva-Rocci by 
the additional use of a stethoscope, which allowed an auscultatory rather than palpatory 
determination of blood pressure. For blood pressure determination, auscultatory or 
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oscillometric semi-automatic sphygmomanometers should be used. The measurement on 
the upper arm is preferred and attention should be paid to the use of the appropriate sleeve 
size. For example, a cuff that is too small primarily leads to an overestimation of blood 
pressure in adipose patients. The clinical investigation includes a comprehensive medical 
examination with pulse status and auscultation of the vessels after flow sounds. 
Furthermore, the abdominal and/or hip circumference is measured while standing. In 
addition, the eye fundus is also examined in diabetics and hypertensives of the third 
degree. Blood pressure should be measured in a quiet environment after a three to five 
minute break. At least 2 measurements are taken every 1-2 minutes. At the first 
examination, the blood pressure on both arms is measured to exclude a side difference. In 
the auscultatory blood pressure determination, care must be taken that the decompression 
proceeds at a rate of 2 mmHg/s. The diastolic blood pressure value is reached as soon as 
the sounds disappear. In elderly patients, orthostatic hypotension must be precluded by 
taking one measurement each after standing for 1 and 3 minutes. When measuring blood 
pressure, a distinction is made between inpatient and outpatient blood pressure 
measurements, with the measured blood pressure in most cases being higher than the one 
measured on an outpatient basis, which is interpreted as a stress response to the tense 
situation during inpatient blood pressure measurement. This "white-coat hypertension" 
occurs in about 13% of all patients and is associated with increased age, female gender and 
non-smokers. White coat hypertension prevalence is lower if blood pressure is measured 
multiple times or by a nurse. Furthermore, "white-coat hypertension" is dependent on the 
degree of hypertension, which is more common in first-degree hypertension than in higher-
grade hypertension. Inpatient and outpatient blood pressure should always be evaluated 
together. In addition, there is also a masked hypertension, in which controversial outpatient 
blood pressure is higher than the measured in-patient. These are more likely to be young 
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male patients with characteristics such as nicotine abuse, alcohol intake, physical activity, 
stress, and obesity. Masked hypertension often remains undetected, so the incidence of 
cardiovascular events in this patient group is about twice that of normotonic patients. The 
ambulatory measured blood pressure is more like the true blood pressure value [9]. 
During the 24-hour blood pressure measurement, the patient wears a portable blood 
pressure monitor, which generates information about blood pressure during daily activities 
and the nightly sleep phase. Blood pressure is usually measured at 15-minute intervals 
during the day and at 30-minute intervals during the night. Overly long intervals should be 
avoided as they limit the accuracy of the 24h blood pressure measurement. Blood pressure 
usually drops during the night, and a drop in blood pressure in excess of 10% of daily 
blood pressure during the night is considered dipping. Patients who fail to dipping suffer 
from secondary hypertension more frequently [26]. 
 
3.2.5 Therapy 
If lifestyle modification alone can not adequately reduce hypertension in the blood 
pressure, drug therapy is initiated. Basically, it does not matter which drug is given, as long 
as adequate blood pressure reduction is achieved, because the largest meta-analysis in this 
regard shows no clinically relevant differences between the different drug groups. Thus, it 
can be confirmed that the use of diuretics, beta-blockers, calcium antagonists, ACE 
inhibitors and angiotensin receptor blockers is suitable for the initiation and maintenance 
of anti-hypertensive therapy [9, 27]. In 1958, the first beta-blocker, dichloroisoproterenol, 
was developed by Eli Lilly Laboratories. But it was Sir James Black who made a 
breakthrough in the treatment of angina pectoris with propranolol in the 1960s [28]. Beta-
blockers act by their competitive inhibition of beta-receptors, which has the effect of 
catecholamine mediating activity. Today, about 60 years after the first beta-blocker was 
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introduced, it can be said that no other synthetic drug group has ever been so widely used 
over time in the treatment of cardiovascular and non-cardiovascular disease as the drug 
group of beta-blockers. Diuretics form the basis of any antihypertensive drug therapy. 
Diuretics were introduced in the 1950s and are still considered to be the primary choice 
when starting pharmacological hypertension therapy [9]. In addition to an increased 
excretion of water, a decrease in the peripheral vascular resistance leads to a reduction in 
blood pressure. Today, diuretics represent the second most prescribed drug group in 
antihypertensive therapy [29]. ACE inhibitors, which are more effective and more tolerated 
antihypertensive, were first used in the 1970s. They block the conversion of angiotensin I 
to angiotensin II and thus inhibit the activity of RAAS [30]. A decade later, the angiotensin 
receptor antagonists were added, which block the activation of angiotensin II receptors. 
Among other things, this leads to vasodilation and decreased secretion of vasopressin and 
aldosterone. These two drug groups are also among the most commonly used in 
hypertension treatment. Renin inhibitors have only been on the market for almost 10 years. 
Aliskiren, the only renin inhibitor to make it into the third phase of a clinical trial, was 
approved as a therapeutic against hypertension by the US Food and Drug Administration 
and the European Medicine Agency in 2007 [31, 32]. Renin inhibitors inhibit RAAS by 
binding to the active site of renin, thus preventing the binding of renin to angiotensinogen 
[33]. Central active antihypertensive and alpha-receptor blockers are also effective drugs in 
blood pressure therapy [34]. 
 
3.3 Therapy-resistant hypertension 
Despite widespread antihypertensive drugs, approximately 10% of all hypertensives are 
resistant to antihypertensive and fail to achieve adequate blood pressure reduction [35]. 
Hypertension in patients who can not reach systolic and diastolic blood pressures of 
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<140/90mmHg, despite therapy containing lifestyle modification, a diuretic, and two other 
antihypertensive drugs of different classes, is termed therapy-resistant hypertension [1, 9]. 
Therapy-resistant hypertension is associated with a higher probability of cardiovascular 
and renal events, which is why new methods for lowering blood pressure in this disease 
must be sought. However, this is extremely difficult because of the complex 
pathophysiology. 
 
3.4 Renal denervation 
In the search for new treatment options for refractory hypertension, the focus continued to 
be on the kidney. It has long been known that no one can control blood pressure via 
afferent and efferent nerves, [36] and that the sympathetic nervous system plays a major 
role in the regulation of circulating blood [37]. Thus, activation of the sympathetic nervous 
system leads to an increase in heart rate and blood pressure [38]. Efferent sympathetic 
fibers activate renin release in the kidney, thus regulating kidney and water excretion. 
Afferent nerves from the kidneys can affect the sympathetic activity in the brain stem [36]. 
Already in 1953, it could be shown experimentally that a sympathectomy leads to a 
lowering of the blood pressure, which led to a reduced mortality [39, 40]. Based on this, 
RDN via ablation catheter was invented in 2009 by the research group led by Murray 
Esler, with whose help the sympathetic-efferent and sensory-afferent signal transmission to 
and from the kidney can be interrupted [41-43]. A radiofrequency ablation catheter (Table 
2) is introduced through the femoral artery, which then bilaterally ablates the sympathetic 
nerves along the renal arteries into the adventitia (Figure 2). 
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Table 2. Devices, Producer, Technology and methods of energy delivery of each of the three 
systems used in our study. The table reports also the mean values of systolic and diastolic blood 
pressure (SBP and DBP respectively) achieved after RDN at 6, 12 and 24 months for each of these 
three devices. 
 
 
Figure 2. Renal denervation. The ablation catheter is located in the renal artery, where it locally 
destroys sympathetic nerve fibers (according to Krum H et al., Circulation. 2011; 123:209-215). 
 
 
 
 
RDN has shown antihypertensive effects in four mammalian species (rat, dog, rabbit, and 
pig) [44], so why should not the method work in humans [45]? Several studies worldwide 
have shown better blood pressure reduction after RDN compared to drug therapy alone in 
 Device Producer Technology Methods n SBP/DBP SBP/DBP 
(mmHg) 
6m 
SBP/DBP 
(mmHg) 
12m 
SBP/DBP 
(mmHg) 
24m 
 Symplicity Medtronic 
Single 
electrode 
monopolar 
2 min per 
ablation 24 
173.4±20.9/ 
89.2±15.8 
148.1±19.4/ 
84.7±14.0 
151.2±21.7/ 
85.5±14.7 
151.6±23/ 
87.6±13.9 
 
EnligHTN St. Jude Medical 
Multielectrode 
basket, 
monopolar 
90s up to 
4 ablation 
points 
14 174.5±17.5/ 94.3±16.4 
145.5±19.7/
85.4±6.2 
138.6±19.7/ 
83.1±12.2 
133.0±5.7/ 
80.8±9.9 
 
Vessix Boston  Scientific 
Over-the-wire 
based 
catheter, 
bipolar 
30 s up to 
6 ablation 
points 
19 
 
155.3±22.4/
87.3±21.3 
136.6±21.3/ 
78.9±12.4 
126.4±16.5/ 
80.4±12.0 
126.2±12.8/ 
74.5±3.2 
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refractory hypertensive [46-50], which leads to high expectations this new therapy method 
has. However, RDN was questioned after the large Symplicity-HTN-3 study did not show 
significantly better blood pressure reduction after RDN [51]. However, this study has some 
limitations, which could explain it as non-inclusive [52]. In particular, a sub-analysis of the 
Symplicity-HTN-3 study has shown that patients who received 12-16 ablations showed a 
comparable blood pressure reduction as in the registries [53]. The randomized French 
study DENER-HTN confirmed the effect of the RDN [50]. Furthermore, long-term results 
of this new antihypertensive method are not yet known and further studies are needed to 
make a final judgment on the efficiency and safety of RDN. 
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4. MATERIAL AND METHODS 
 
4.1 Patients 
All consecutive 57 patients with pharmacologically resistant hypertension (BP>140/90 
mmHg) according to the last ESC guidelines [54] with therapy of at least 3 
antihypertensive drugs, one of which one had to be a diuretic, all at the maximal tolerated 
dose, referred to the Department of Cardiology of the University Hospital of Zurich from 
August 2010 and April 2017 were enrolled in the current study with a rate of 8 patient/year 
(Table 1). A secondary form of hypertension was formally excluded in all the patients 
considered in this cohort, during at least two outpatient clinical evaluations. Patients with 
moderate to severe renal impairment (eGFR < 45 ml/min), anatomical contraindications to 
percutaneous renal denervation, anatomical variant of the renal arteries, short and small 
renal arteries with a length inferior to 20 mm or a diameter inferior to 4 mm were 
excluded. In all patient’s antihypertensive therapy had to remain stable for at least 4 weeks 
before the procedure. All the patients were under diuretic therapy and 20 out of 57 already 
assumed an aldosterone antagonist. Systolic blood pressure upon admission was >140 
mmHg in all the patients. Routine blood analyses and blood pressure measurement were 
performed before the intervention and at 6, 12 and 24 months in all patients, this latter with 
an automatic oscillometric device (Microlife® or Omron®) according to current 
guidelines. Patients’ characteristics are resumed in Table 3. 
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Table 3. Patients characteristics.  
 
Characteristics (Pts N=57)  
Age yrs mean ± SD 61.26±12.25 
Male 35/57 (61.4%) 
BMI kg/m2 mean ± SD 30.93±5.19 
Smokers 20 (35.1%) 
Diabetes 18 (31.6%) 
Dyslipidemia 24 (42.1%) 
CAD 10 (17.5%) 
CKD 10 (17.5%) 
COPD 3 (5.3%) 
AF 4 (7%) 
Previous Stroke 7 (12.3%) 
Aspirin 27 (47.4%) 
OAC 5 (8.8%) 
Diuretics 57 (100%) 
Renin Inhibitors 7 (12.3%) 
RAAS Inhibitors 49 (86%) 
CA-Antagonists 44 (77.2%) 
Beta Blockers 45 (78.9%) 
Alpha Blockers 22 (38.6%) 
Nitrates 5 (8.8%) 
Aldosterone-Antagonists 20 (35.1%) 
Avarage Medications mean ± SD 4.24±1.39 
 
CAD= coronary artery disease. CKD= chronic kidney disease. COPD= chronic obstructive 
pulmonary disease. AF= atrial fibrillation. OAC= oral anticoagulation. RAAS= Renin-
Angiotensin-Aldosterone-system. SD= standard deviation. 
 
4.2 Technique 
Three different types of renal denervation systems have been used for the procedures by 
experienced operators (Table 2): 1) the Symplicity™-RDN-System from Medtronic 
(single electrode, monopolar), 2) the EnligHTN™-Multi-Electrode-Renal-Denervation-
System (multielectrode basket, monopolar) from St. Jude Medical and 3) the Vessix™-
Renal-Denervation-System from Boston Scientific (over-the-wire based catheter, bipolar). 
Radiofrequency was erogated through a generator. With the first generation SymplicityR 
system, the ablation catheter was advanced over a guidewire through a 6F catheter deep 
close to the bifurcation of the main renal artery, with final application of six ablations in a 
spiral fashion starting from the distal part of the renal artery up to its origin from the aorta 
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[41]. Commonly, 5-8 watts are applied for 2 minutes at each of the at least six ablations 
sites. Impedance may be used to assure good wall contact (optimal range: 300 – 350 Ω). 
The St. Jude basket contains four electrodes and once placed distally in the renal artery 
before the bifurcation, 4 ablations are automatically applied for 60 sec. In contrast to the 
Symplicity system, the St. Jude system is temperature driven. After the first ablation series, 
multiple ablations are possible by turning the node at the steering end of the ablation 
catheter and slightly pulling towards the ostium of the renal artery [55]. The Vessix 
balloon catheter (Boston Scientific Corporation Natick, MA) is an over the wire system 
using bipolar energy, consisting in a low-pressure balloon (3 atm) available in 4, 5, 6, 7 
mm diameter sizes with offset electrode pairs placed in helical pattern. With simple 
anatomy, the balloon can be easily advanced into the renal artery over a 0.014 F guidewire 
[56].  Blood pressure was measured with an automatic oscillometric device (Microlife® or 
Omron®) while sitting for 5 minutes and using a 24h blood pressure recorder (SpaceLab®) 
before and at 6, 12 and 24 months after the RDN procedure. RDN was performed using a 
full four-quadrant ablation technique on both renal arteries, from the distal to the proximal 
segment, with energy delivery performed for all the time required from each system. 
 
4.3 Statistics 
The primary endpoint was the change in systolic and diastolic office blood pressure values 
at 6, 12 and 24 months compared to baseline immediately before the index procedure. The 
primary safety endpoint was the change in plasma creatinine levels at 12 and 24 months 
compared to baseline immediately before the index procedure.  The 6 months follow-up 
was left optional for the patients; 24 patients completed follow-up with a 24hours ABPM 
and28 only with an office measurement. At 24 months, only 11 patients were investigated 
with a 24hours ABPM, while 21 accepted a clinical follow-up. All the results were 
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reported as mean ± standard deviation. A t-test was performed to analyze and for all the 
statistical analyses a α=0,05 was considered, with statistical significance with a α≤0,05. A 
non-parametric test with paired samples was used to compare the BP values series. All 
these statistical analyses were performed with the SPSS Version 22.0. 
 
4.4 Informed consent and privacy 
The data were collected during a medical consultation and used in a pseudo-anonymous 
form. A written consent for the RDN was obtained in writing for all patients prior to the 
procedure and the results obtained were analyzed retrospectively. 
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5. RESULTS 
 
5.1. Outcome 
After RDN, a significant reduction of systolic and diastolic blood pressure was observed at 
6, 12 and 24 months (Figure 3).  
 
Figure 3. Mean systolic and diastolic blood pressure reduction according to 24hours ABPM and 
office measurements. DeltaSBP-ABPM= systolic blood pressure difference according to 24h 
ambulatory blood pressure measurement (-12.1, -18.4 and -17.4 mmHg); DeltaDBP-ABPM= 
diastolic blood pressure difference according to 24h ambulatory blood pressure measurement (-6.8, 
-12.8 and -4.5 mmHg); DeltaSBP-Office= systolic blood pressure difference according to office 
blood pressure measurement (-20.5, -29.1 and -29 mmHg); DeltaDBP-Office= diastolic blood 
pressure difference according to office ambulatory blood pressure measurement (-5.1, -5.3 and -
12.2 mmHg). Compared to baseline all these differences were statistical significant (p<0.05). 
 
 
 
 
The mean office systolic blood pressure value was 167.6±22.4mmHg at baseline and 
143.5±21.1, 141.1±21.1 and 139.4±19.6 mmHg after 6, 12 and 24 months, respectively (all 
p<0.05, compared to baseline). The mean 24hours systolic ABPM values at baseline 
averaged 154.8±18.4mmHg and 142.4±21.8, 137.7±17.4 and 139.9±11.8 mmHg at 6, 12 
 
 
22 
and 24 months, respectively (all p<0.05, compared to baseline).  Similar results were 
observed also when considering the mean diastolic values both the for office and 24h 
measurements. Compared to baseline value of 89.8±18.36mmHg diastolic blood pressure 
fell to 83.3±12.2 (p<0.05), 83.0±12.2 (p<0.05) and82.5±12.3 mmHg (p<=0.05) at office 
measurements and from 89.8±18.3mmHg to 83.3±12.2 (p=0.02) 83.0±12.2 (p<=0.05) and 
82.5±12.3 (p<=0.05) for the 24hours ABPM (Table 4 and Table 5).  
 
Table 4. 24hours ABPM at baseline, 6,12 and 24 months after RDN. P-values refer to baseline. 
ABPM (Pts N=57)  
SBP Baseline (Pts N=46) 154.8±18.4 
DBP Baseline  88.7±13.6  
SBP 6 months (Pts N=32) 142.4±21.8 (p<0.05) 
DBP 6 months 81.0±12.4 (p<0.05) 
SBP 12 months (Pts N=19) 137.7±17.4 (p=0.05) 
DBP 12 months 78.6±9.8 (p=0.02) 
SBP 24months (Pts N=9) 139.9±11.8 (p=0.19) 
DBP 24 months 82.0±8 (p=0.32) 
ABPM= ambulatory blood pressure measurement. SBP= systolic blood pressure. DBP= diastolic 
blood pressure. SBP and DBP values are expressed in mmHg ± standard deviation 
 
 
Table 5. Office blood pressure measurement at baseline, 6, 12 and 24 months after RDN. P-values 
refer to baseline. 
 
Office Blood Pressure Measurement (Pts n=57)  
SBP Baseline (Pts N=57) 167.6±22.4 
DBP Baseline  89.8±18.3 
SBP 6 months (Pts N=44) 143.5±21.1 (p=0.02) 
DBP 6 months 83.3±12.2 (p=0.05) 
SBP 12 months (Pts N=29) 141.1±21.1 (p=0.45) 
DBP 12 months 83.0±12.2 (p>0.05) 
SBP 24months (Pts N=23) 139.4±19.6 (p=0.45) 
DBP 24 months 82.5±12.3 (p>0.05) 
SBP= systolic blood pressure. DBP= diastolic blood pressure. SBP and DBP values are expressed 
in mmHg ± standard deviation. 
 
 
The small difference between ABPM and office values is due to the limited number of 
AMBP measurements available (9 patient out of 57 at 24 months). A non-parametric test 
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with related samples was applied to both ABPM and office measurements. Regarding the 
ABPM we found a significant reduction from the baseline for SBP at 6 (p<0.05) and at 12 
months (p=0.05), but not at 24 months (p=0.19) as well as for DBP at 6 (p<0.05), 12 
(p=0.02) and 24 (p=0.32) months. Analyzing the office blood pressure measurements, we 
found a statistical significant reduction for SBP at 6 (p=0.02), but not at 12 (p=0.45) and 
24 (p=0.45) months as well as for DBP at 6, 12 and 24 months (all p>0.05). The average 
number of ablations was 15.1±5.3 (11.9±2.8 until 2013, 19.4±4.6 from 2014) performed 
with the Symplicity™-RDN-System from Medtronic (n=24 patients, 2 minutes per 
ablation), with the EnligHTN™-Multi-Electrode-Renal-Denervation-System from St. Jude 
Medical (n=14 patients, 90 seconds up to 4 ablation points) and with the Vessix™-Renal-
Denervation-System from Boston Scientific (n=19 patients, 30 seconds up to 6 ablation 
points). There was no statistical significant difference in lowering efficacy between the 
three different systems used (all p>0.05). There was no significant correlation between 
baseline characteristics and BP reduction, except for the assumption of an aldosterone 
antagonist prior to RDN and the reduction of both office SBP and DBP at 6 (p= 0.046 and 
0.003 respectively) months, but not at 12 and 24 months. The lack of significance at the 
follow-up is probably due to the limited number of patients.  Follow-up was the major 
limitations of the study: ABPM is available for 39, 26 and 12 patients at 6, 12 and 24 
months respectively, while an office measurement for 44, 31 and 23 patients. Considering 
the office measurement, according to the international guidelines, we found that at 6, 12 
and 24 months only 16 (SBP 119.9±12.7 mmHg, DBP 76.9±10.5 mmHg), 11 (SBP 
118.2±10.4 mmHg, DBP 73.6±9.3 mmHg) and 13 (SBP 126.3±8.8 mmHg, DBP 77±6.6 
mmHg) out of 57 patients presented controlled blood pressure after the RDN. No 
significant changes were observed regarding the number of medications at 6 12 and 24 
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months (all > 0.05, Table 5). Of notice only 3 out of 37 patients without a previous anti-
aldosterone therapy were treated with this drug. 
 
5.2 Safety aspects 
There were no short- or long-term complications after the intervention and no relevant 
adverse vascular, renal or cardiovascular, were observed except in one patient in whom the 
procedure had to be postponed after introducing the sheet due to marked bleeding from the 
puncture site which was treated with implantation of a covered stent. The RDN procedure 
was then performed a few weeks later. All 57 patients were discharged at home the day 
after the procedure. Plasma creatinine levels remained stable throughout the observation 
period, with no significant changes at 12 (p=0.421) and 24 months (p=0.217). 
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6. DISCUSSION 
 
6.1 Main results 
In this registry of consecutive patients treated in a single center by one operator performing 
an average of 15 ablations in both renal arteries, renal nerve ablation led to a marked 
reduction of systolic and diastolic blood pressure without changes in antihypertensive 
medication or significant side effects. RDN using 3 different ablation systems was 
performed in patients with confirmed resistant hypertension: 1) Symplicity™-RDN-
System from Medtronic (n=24); 2) the EnligHTN™-Multi-Electrode-Renal-Denervation-
System from St. Jude Medical (n=14) and 3) the Vessix™-Renal-Denervation-System 
from Boston Scientific (n=19).  Our results confirm the results of some international 
studies on renal denervation [47-50].  
 
6.2 Comparison with other publications 
Indeed, the Prague-15 Study and the DENER-HTN study, which had a comparable number 
of patients, achieved similar blood pressure reductions of 12.4±4.6 mmHg and 15.1±5.5 
mmHg, respectively with a less pronounced reduction at 6 months compared to our results. 
Furthermore, our study led to similar systolic and diastolic blood pressure reductions 24 
months after RDN (28.4±23.95 mmHg vs. 28.9±4.6 mmHg) as the Symplicity HTN-1 
registry [47]. Also, in the randomized Symplicity HTN-2 trial, comparable results were 
obtained [48]. In contrast, the Symplicity-HTN-3 study failed to achieve the primary 
endpoint and revealed an overall non-significant reduction in blood pressure after RDN 
compared to the drug only therapy group.  
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6.2.1 The Symplicity HTN-3 Study 
The negative result of the large Symplicity HTN-3 Study, lead to a wide interpretation of 
the study results. Several aspects of the study have been criticized: first, Symplicity HTN-3 
included patients in whom blood pressure and antihypertensive drugs had not been 
stabilized before the intervention. Second, the percentage of Afro-American was with 25% 
much higher than in other studies. This is particularly in contrast to European and 
Australian studies as well as the current Swiss registry [57]. Indeed, Afro-Americans often 
have low-renin and volume-dependent hypertension, which may not respond to RDN. 
Third, the majority of Symplicity HTN-3 patients had already been treated with an average 
of 5.2±1.4 antihypertensive drugs [58], which makes it difficult to provide a further blood 
pressure lowering with any intervention. Finally, one of the major issues, on which the 
researchers of the field focused their attention in the last years, regards the technical 
performance of RDN in the Symplicity HTN-3 study. Of note, most of the cardiologists 
involved in the study had no previous experience with the procedure and in most of the 
cases they accounted only for 1-2 interventions of this type in the trial. Furthermore, the 
number of ablations which correlates directly with the degree of blood pressure reduction 
have been quite variable in the Symplicity HTN-3 trial ranging from 1 to 18 ablations. 
Importantly, only 84% of the procedures produced complete ablations of 120 seconds and 
a bilateral 4-quadrant ablation was only achieved in 6% of all patients. In a small 
subpopulation of 19 patients, which received bilateral 4-quadrant ablation, the blood 
pressure reduction also averaged 24.3 ±10.3 mmHg), similar to other studies and the 
current Swiss registry. Indeed, in the present series of patients, the experienced single 
operator performed an average of 15 ablations, a number that also showed in the sub 
analysis of Symplicity HTN-3 a marked and sustained blood pressure lowering effect of 
similar size. Thus, it appears that it is essential to perform a large number of ablation in 
order to destroy the renal nerves within the adventitia and to achieve a relevant blood 
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pressure lowering effect.  A post-hoc analysis identified predictors of systolic blood 
pressure change in the subjects of the SIMPLICITY HTN-3, particularly severe baseline 
systolic hypertension (SBP > 180 mmHg), aldosterone antagonist use, non-use of 
vasodilators and, in the denervation group, the number of ablation, which if delivered in a 
four quadrant-pattern led to greater reduction of office and ambulatory SBP and heart rate 
in this population [53]. 
 
6.2.2 The SPYRAL HTN-OFF MED Study 
The results of the SPYRAL HTN-OFF MED trial confirmed blood pressure lowering 
efficacy of RDN and encouraged to design larger pivotal trial [59]. In the 80 patients 
analyzed there was a significant reduction in office and 24-h-ABPM at 3 months in 
patients with mild to moderate hypertension after RDN without antihypertensive therapy 
that was not observed in the sham control group (24-h SBP -5.0 mm Hg (95% CI -9.9 to -
0.2; p=0.041), 24-h DBP -4.4 mm Hg (-7.2 to -1.6; p=0·002), office SBP -7.7 mm Hg (-
14.0 to -1.5; p=0·015), and office DBP -4.9 mmHg (-8.5 to -1.4; p=0·007). The 
retrospective and observational approach, together with the absence of a control arm, 
pharmacological or sham-procedure, represent the main limitation of the study, considering 
the profound placebo effect of RDN shown in controlled trials.    
 
6.3 Limitations 
Our study confirms findings from previous studies demonstrating safety and efficacy of 
RDN in a cohort of patients with resistant hypertension. The retrospective analysis, the 
lack of a control group and the limited number of patients available at follow-up represents 
the major limitations of this study. Repeated AMBP represented the major complaint for 
the patients. 
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6.4 Importance of the study 
The study results of the University Hospital of Zurich confirm the results of a number of 
other studies [46-50] that RDN can be used as an effective and safe therapy option for 
treatment-resistant hypertension, overall if performed adequately in number of ablations 
and energy delivery. 
 
6.5 Unanswered questions 
Based on the current controversy on the effectiveness of RDN a European group of experts 
discussed the study design for future clinical studies during a consensus conference on the 
RDN [60]. According to this expert opinion paper, RDN should be performed in relatively 
young patients with mild hypertension as young patients present a higher sympathetic 
activity. In the current registry patients were relatively young with a median age of around 
60 years. Indeed, in elderly hypertensives, which usually present with isolated systolic 
hypertension, RDN has been shown to be much less effective [61]. The type of system, 
which should be used for RDN, the type of ablation and its duration represent other major 
issues. Balloon-based catheters, as used partially also in this study, are probably better and 
provide a more consistent bilateral 4-quadrant ablation in the distal part of the artery. Also, 
the 24hours ABPM should be the only measurement tool to assess changes in blood 
pressure. As recently report, indeed, the 24hours ABPM is important to validate resistant 
hypertension [62]. Recent study results on RDN have led to more questions than answers. 
Future studies will provide a definitive assessment of the efficiency and safety of RDN. It 
remains unclear whether all patients should receive the same antihypertensive drugs before 
intervention. Furthermore, in the case of medication, the question arises as to whether a 
washout phase should be carried out so that the pre-therapeutic blood pressure values are 
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reached again in advance. However, the European expert group denies this because 
otherwise the risk of stroke and other cardiovascular events would increase during this 
time. Such a washout phase, if any, should only be realized by experienced research 
centers. Noncompliance of patients taking medication and the lack of strategies to 
eliminate this confounder in large study populations pose further problems. The focus of 
future study planning should be on standardization. This should include study design and 
population, therapy, technique, compliance and success markers. This is the only way to 
compare study results free from confounding factors. 
In conclusion, research on the efficiency and safety of RDN is still ongoing. Nevertheless, 
it should be noted that although subsequent studies should prove that RDN is not an 
effective and safe antihypertensive therapy, it does not necessarily mean the end of RDN. 
In addition to the hypotensive effect, a decrease in the left ventricular mass, an 
improvement in diastolic function and antiarrhythmic effects after RDN were also 
observed [63, 64]. If not in hypertension therapy then this may be the future of RDN. 
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